Two River

Oyster Point Pharma to Report Second Quarter 2021 Financial Results on August 5, 2021

Retrieved on: 
Wednesday, August 4, 2021
Life sciences, Medication, Pharmaceutical industry, Natural sciences, Health sciences, Aerie Pharmaceuticals, Two River

PRINCETON, N.J., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that it will report second quarter 2021 financial results on Thursday, August 5, 2021, after the market close.

Key Points: 
  • PRINCETON, N.J., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that it will report second quarter 2021 financial results on Thursday, August 5, 2021, after the market close.
  • To access the live call by phone, please dial (855) 548-1220 (US/Canada) or (602) 563-8619 (International).
  • Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases.
  • Despite the large prevalence of dry eye and the burden of the disease, there remains a significant unmet need for effective therapies.

Zentera Therapeutics Announces Closing of $75 Million Series B Financing

Retrieved on: 
Monday, August 2, 2021
Companies, Two River, Draft:Atossa Therapeutics

SHANGHAI, China, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Zentera Therapeutics, a clinical-stage biopharmaceutical company with headquarters in Shanghai, China, today announced the successful completion of a $75 million Series B financing.

Key Points: 
  • SHANGHAI, China, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Zentera Therapeutics, a clinical-stage biopharmaceutical company with headquarters in Shanghai, China, today announced the successful completion of a $75 million Series B financing.
  • Zentera was formed by Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) to develop cancer therapies in China.
  • Zentera has four Clinical Trial Applications (CTA) approved in China to date.
  • Zentera Therapeutics, Inc. is a Shanghai based clinical-stage biopharmaceutical company focused on developing cancer therapeutics.

Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results

Retrieved on: 
Thursday, July 29, 2021
Companies, Two River, Wilson Therapeutics

SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2021 financial results after theU.S.financial markets close onThursday, August 5, 2021.

Key Points: 
  • SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2021 financial results after theU.S.financial markets close onThursday, August 5, 2021.
  • ET) to provide a comprehensive business update and discuss the Companys financial results.
  • Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need.
  • Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression.

TScan Therapeutics, Inc. Announces Pricing of Initial Public Offering

Retrieved on: 
Thursday, July 15, 2021
Financial markets, Finance, Financial economics, Corporate finance, Stock market, Initial public offering, Underwriting, Stock, Public offering, Two River

WALTHAM, Mass., July 15, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (TScan), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the pricing of its initial public offering of 6,666,667 shares of common stock at a public offering price of $15.00 per share, for gross proceeds of $100.0 million, before underwriting discounts, commissions, and offering expenses payable by TScan.

Key Points: 
  • WALTHAM, Mass., July 15, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (TScan), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the pricing of its initial public offering of 6,666,667 shares of common stock at a public offering price of $15.00 per share, for gross proceeds of $100.0 million, before underwriting discounts, commissions, and offering expenses payable by TScan.
  • In addition, TScan has granted the underwriters an option for a period of 30 days to purchase up to 1,000,000 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions.
  • TScans common stock is expected to begin trading on The Nasdaq Global Market on July 16, 2021 under the symbol TCRX.
  • The offering is expected to close on or aboutJuly 20, 2021, subject to the satisfaction of customary closing conditions.

DiaMedica Therapeutics Elects Two Industry Veterans to Its Board of Directors

Retrieved on: 
Thursday, July 15, 2021
Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, Companies, Economy of the United States, Two River, Regulus Therapeutics

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the election of two industry veterans to the Companys Board of Directors.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the election of two industry veterans to the Companys Board of Directors.
  • Amy Burroughs, President and CEO of Cleave Therapeutics, brings over 20 years of experience in business and commercial development, strategy and leadership in the pharmaceutical industry.
  • Amy and Charles have the perfect mix of experience to bring to our board at this stage of the company, said Rick Pauls, President and Chief Executive Officer of DiaMedica.
  • DiaMedica Therapeutics is a clinical stage biopharmaceutical company committed to improving the lives of people suffering serious diseases.

BioXcel Therapeutics Announces Proposed Public Offering of Common Stock

Retrieved on: 
Tuesday, June 22, 2021
Finance, Corporate finance, Financial economics, Financial markets, Stock market, Initial public offering, Public offering, Stock, Two River, Agios Pharmaceuticals

NEW HAVEN, Conn., June 22, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the Company) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock.

Key Points: 
  • NEW HAVEN, Conn., June 22, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the Company) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock.
  • In addition, a related party stockholder, BioXcel LLC, expects to grant the underwriters a 30-day option to purchase up to $15.0 million of additional shares of common stock at the public offering price, less underwriting discounts and commissions.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • The Company intends to use the net proceeds of this offering to fund ongoing clinical trials, commercialization preparation and for general corporate purposes.

Oyster Point Pharma to Participate in the LifeSci Partners Genetic Medicines Summit

Retrieved on: 
Monday, June 21, 2021
Two River, Companies

PRINCETON, N.J., June 21, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery,developmentand commercialization of first-in-class therapies to treatophthalmicdiseases, today announced that the Company will participate virtually in the LifeSci Partners Genetic Medicines Summit on Tuesday, June 22, 2021, at 2:00 p.m.

Key Points: 
  • PRINCETON, N.J., June 21, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery,developmentand commercialization of first-in-class therapies to treatophthalmicdiseases, today announced that the Company will participate virtually in the LifeSci Partners Genetic Medicines Summit on Tuesday, June 22, 2021, at 2:00 p.m.
  • ET.
  • To access the live webcast, please visit the Investors and News section of the Oyster Point Pharma website at https://investors.oysterpointrx.com/ .
  • Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ophthalmic diseases.

Viking Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
Thursday, June 10, 2021
Companies, Michael Cowley, Two River

SAN DIEGO, Calif., June 10, 2021 /PRNewswire/ --Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, todayannounced that the company will participate in two upcoming investor conferences.

Key Points: 
  • SAN DIEGO, Calif., June 10, 2021 /PRNewswire/ --Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, todayannounced that the company will participate in two upcoming investor conferences.
  • Details of the company's participation are as follows:
    Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders.
  • Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives.
  • For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com .

Onconova Therapeutics Announces Participation in A.G.P.’s Upcoming Virtual Summer Healthcare Symposium

Retrieved on: 
Thursday, June 10, 2021
Pharmaceutical companies, Companies, Biotechnology companies, Two River, United Therapeutics

NEWTOWN, Pa., June 10, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (Onconova), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that members of the Companys management team will participate in A.G.P.s Virtual Summer Healthcare Symposium on Thursday, June 17, 2021.

Key Points: 
  • NEWTOWN, Pa., June 10, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (Onconova), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that members of the Companys management team will participate in A.G.P.s Virtual Summer Healthcare Symposium on Thursday, June 17, 2021.
  • Investors participating in the virtual conference who are interested in meeting with members of Onconovas management team should contact their A.G.P.
  • Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer.
  • The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

Werewolf Therapeutics Reports First Quarter 2021 Financial Results

Retrieved on: 
Thursday, June 10, 2021
Life sciences, Companies, Biotechnology, Two River

CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the Company or Werewolf) (NASDAQ: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the bodys immune system for the treatment of cancer, today announced financial results for the quarter ended March31, 2021.

Key Points: 
  • CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the Company or Werewolf) (NASDAQ: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the bodys immune system for the treatment of cancer, today announced financial results for the quarter ended March31, 2021.
  • Successful Initial Public Offering Completed: On May 4, 2021, Werewolf completed its initial public offering (IPO).
  • Net loss: Net loss was $7.4 million for the first quarter of 2021, compared to $3.8 million for the same period in 2020.
  • Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the bodys immune system for the treatment of cancer.